Bristol Myers lung drug meets late-stage trial goal

A lower dose of Bristol Myers' admilparant slowed lung-function decline in a 1,255-patient late-stage trial. If approved, it would be the first LPA1 inhibitor for idiopathic pulmonary fibrosis.